Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism
Leukemia Research, 05/07/09
Breccia M et al. - The different metabolic effects have been reported as a consequence of imatinib inhibition during treatment of patients with CML. The aim of this review is to report the changes caused by imatinib on glucose, lypidic and bone metabolism.
Related Articles
Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate
Cancer, 11/06/09
Relevance Score: 66%
Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate
Investigational New Drugs, 10/08/09
Relevance Score: 65%
Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine
American Journal of Hematology, 11/09/09
Relevance Score: 64%
New treatment more than doubles survival for high risk childhood leukemia
EurekAlert, 10/07/09
Relevance Score: 64%
Improved early event-free survival with imatinib in philadelphia chromosome-positive acute lymphoblastic leukemia: a childrens oncology group study
Journal of Clinical Oncology, 10/09/09
Relevance Score: 48%
Today in Leukemia/Lymphoma...keeping you current
Receive free subspecialty "5-minute updates" via email
Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS)
British Journal of Haematology, 11/30/09
SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia
Blood, 11/30/09
Association between defb1 gene haplotype and herpes viruses seroprevalence in children with acute lymphoblastic leukemia
Pediatric Hematology and Oncology, 11/30/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
The Lancet Oncology - Online First, 11/30/09
Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study
The Lancet Oncology - Online First, 11/30/09
Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review
Journal of Clinical Oncology, 11/30/09
Today in Side Effects...keeping you current
Receive free subspecialty "5-minute updates" via email
Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer
Cancer, 11/25/09
Incidence of oral mucositis, its treatment and pain management in patients receiving cancer treatment at Radiation Oncology Departments in Spanish hospitals (MUCODOL Study)
Clinical and Translational Oncology, 11/25/09
Hemorrhagic Gastritis and Duodenitis Following Celiac Plexus Neurolysis
Pain Physician, 11/25/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


